These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29671628)

  • 1. Selective PPARγ modulators for Type 2 diabetes treatment: how far have we come and what does the future hold?
    Lavecchia A; Cerchia C
    Future Med Chem; 2018 Apr; 10(7):703-705. PubMed ID: 29671628
    [No Abstract]   [Full Text] [Related]  

  • 2. Design, synthesis, and activity evaluation of GK/PPARγ dual-target-directed ligands as hypoglycemic agents.
    Lu J; Lei L; Huan Y; Li Y; Zhang L; Shen Z; Hu W; Feng Z
    ChemMedChem; 2014 May; 9(5):922-7. PubMed ID: 24737574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitarget PPARγ agonists as innovative modulators of the metabolic syndrome.
    Ammazzalorso A; Maccallini C; Amoia P; Amoroso R
    Eur J Med Chem; 2019 Jul; 173():261-273. PubMed ID: 31009912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multitargeted bioactive ligands for PPARs discovered in the last decade.
    Zhang J; Liu X; Xie XB; Cheng XC; Wang RL
    Chem Biol Drug Des; 2016 Nov; 88(5):635-663. PubMed ID: 27317624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.
    Banerjee PS; Samanta S
    Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
    Porskjær Christensen L; Bahij El-Houri R
    Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel (-)-Cercosporamide derivatives as potent selective PPARγ modulators.
    Furukawa A; Arita T; Fukuzaki T; Mori M; Honda T; Satoh S; Matsui Y; Wakabayashi K; Hayashi S; Nakamura K; Araki K; Kuroha M; Tanaka J; Wakimoto S; Suzuki O; Ohsumi J
    Eur J Med Chem; 2012 Aug; 54():522-33. PubMed ID: 22727448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
    Tan Y; Muise ES; Dai H; Raubertas R; Wong KK; Thompson GM; Wood HB; Meinke PT; Lum PY; Thompson JR; Berger JP
    Mol Pharmacol; 2012 Jul; 82(1):68-79. PubMed ID: 22496518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
    Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
    Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives.
    Furukawa A; Arita T; Satoh S; Wakabayashi K; Hayashi S; Matsui Y; Araki K; Kuroha M; Ohsumi J
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2095-8. PubMed ID: 20219371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
    Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
    Gelman L; Feige JN; Desvergne B
    Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.
    Choung W; Yang D; Kim H; Choi H; Lee BR; Park M; Jang SM; Lim JS; Kim WS; Kim KH; Chin J; Jung K; Lee G; Hong E; Jang TH; Joo J; Hwang H; Myung J; Kim SH
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2275-2282. PubMed ID: 31253533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of docking-based 3D-QSAR models for PPARgamma full agonists.
    Guasch L; Sala E; Valls C; Mulero M; Pujadas G; Garcia-Vallvé S
    J Mol Graph Model; 2012 Jun; 36():1-9. PubMed ID: 22503857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
    Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
    J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.
    Doshi LS; Brahma MK; Bahirat UA; Dixit AV; Nemmani KV
    Expert Opin Investig Drugs; 2010 Apr; 19(4):489-512. PubMed ID: 20367191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics.
    Lu P; Bevan DR; Lewis SN; Hontecillas R; Bassaganya-Riera J
    J Mol Model; 2011 Mar; 17(3):543-53. PubMed ID: 20512604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.
    Guasch L; Sala E; Valls C; Blay M; Mulero M; Arola L; Pujadas G; Garcia-Vallvé S
    J Comput Aided Mol Des; 2011 Aug; 25(8):717-28. PubMed ID: 21691811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.